| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print July 21, 2004
Division of Clinical Nutrition, National Institute of Health and Nutrition, Tokyo, Tokyo 162-8636
Corresponding Author: ykamei{at}nih.go.jp
FOXO1, a member of the FOXO forkhead type transcription factors, is markedly up-regulated in skeletal muscle in energy-deprived states such as fasting and severe diabetes, but its functions in skeletal muscle have remained poorly understood. In this study, we created transgenic mice specifically overexpressing FOXO1 in skeletal muscle. These mice weighed less than the wild-type control mice, had a reduced skeletal muscle mass, and the muscle was paler in color. Microarray analysis revealed that the expression of many genes related to the structural proteins of type I muscles (slow twitch, red muscle) were decreased. Histological analyses showed a marked decrease in size of both type I and type II fibers, and a significant decrease in the number of type I fibers in the skeletal muscle of FOXO1 mice. Enhanced gene expression of a lysosomal proteinase, cathepsin L, which is known to be up-regulated during skeletal muscle atrophy, suggested increased protein degradation in the skeletal muscle of FOXO1 mice. Running wheel activity (spontaneous locomotive activity) was significantly reduced in FOXO1 mice compared to control mice. Moreover, the FOXO1 mice showed impaired glycemic control after oral glucose and intraperitoneal insulin administration. These results suggest that FOXO1 negatively regulates skeletal muscle mass and type I fiber gene expression, and leads to impaired skeletal muscle function. Activation of FOXO1 may be involved in the pathogenesis of sarcopenia, the age-related decline in muscle mass in humans, which leads to obesity and diabetes.
J. Biol. Chem, 10.1074/jbc.M400674200
Submitted on January 21, 2004
Revised on July 9, 2004
Accepted on July 21, 2004
Skeletal muscle FOXO1 (FKHR)-transgenic mice have less skeletal muscle mass, down-regulated type I (slow twitch / red muscle) fiber genes, and impaired glycemic control
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. S. Waddell, L. M. Baehr, J. van den Brandt, S. A. Johnsen, H. M. Reichardt, J. D. Furlow, and S. C. Bodine The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E785 - E797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Iwasaki, K. Hayashi, T. Fujioka, and K. Sobue Rho/Rho-associated Kinase Signal Regulates Myogenic Differentiation via Myocardin-related Transcription Factor-A/Smad-dependent Transcription of the Id3 Gene J. Biol. Chem., July 25, 2008; 283(30): 21230 - 21241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Larrouy, P. Barbe, C. Valle, S. Dejean, V. Pelloux, C. Thalamas, J.-P. Bastard, A. Le Bouil, B. Diquet, K. Clement, et al. Gene expression profiling of human skeletal muscle in response to stabilized weight loss Am. J. Clinical Nutrition, July 1, 2008; 88(1): 125 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sandri Signaling in Muscle Atrophy and Hypertrophy Physiology, June 1, 2008; 23(3): 160 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kamei, S. Miura, T. Suganami, F. Akaike, S. Kanai, S. Sugita, A. Katsumata, H. Aburatani, T. G. Unterman, O. Ezaki, et al. Regulation of SREBP1c Gene Expression in Skeletal Muscle: Role of Retinoid X Receptor/Liver X Receptor and Forkhead-O1 Transcription Factor Endocrinology, May 1, 2008; 149(5): 2293 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Schakman, H Gilson, and J P Thissen Mechanisms of glucocorticoid-induced myopathy J. Endocrinol., April 1, 2008; 197(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nedachi, A. Kadotani, M. Ariga, H. Katagiri, and M. Kanzaki Ambient glucose levels qualify the potency of insulin myogenic actions by regulating SIRT1 and FoxO3a in C2C12 myocytes Am J Physiol Endocrinol Metab, April 1, 2008; 294(4): E668 - E678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Pardo, M. A. Lopez, and A. M. Boriek FOXO transcription factors are mechanosensitive and their regulation is altered with aging in the respiratory pump Am J Physiol Cell Physiol, April 1, 2008; 294(4): C1056 - C1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. De Alvaro, I. Nieto-Vazquez, J. M. Rojas, and M. Lorenzo Nuclear Exclusion of Forkhead Box O and Elk1 and Activation of Nuclear Factor-{kappa}B Are Required for C2C12-RasV12C40 Myoblast Differentiation Endocrinology, February 1, 2008; 149(2): 793 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. G. Ni, N. Wang, D. J. Cao, N. Sachan, D. J. Morris, R. D. Gerard, M. Kuro-o, B. A. Rothermel, and J. A. Hill FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases PNAS, December 18, 2007; 104(51): 20517 - 20522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lara-Pezzi, N. Winn, A. Paul, K. McCullagh, E. Slominsky, M. P. Santini, F. Mourkioti, P. Sarathchandra, S. Fukushima, K. Suzuki, et al. A naturally occurring calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration J. Cell Biol., December 17, 2007; 179(6): 1205 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nedergaard, K. Vissing, K. Overgaard, M. Kjaer, and P. Schjerling Expression patterns of atrogenic and ubiquitin proteasome component genes with exercise: effect of different loading patterns and repeated exercise bouts J Appl Physiol, November 1, 2007; 103(5): 1513 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Manolagas and M. Almeida Gone with the Wnts: {beta}-Catenin, T-Cell Factor, Forkhead Box O, and Oxidative Stress in Age-Dependent Diseases of Bone, Lipid, and Glucose Metabolism Mol. Endocrinol., November 1, 2007; 21(11): 2605 - 2614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Almon, D. C. DuBois, Z. Yao, E. P. Hoffman, S. Ghimbovschi, and W. J. Jusko Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens Physiol Genomics, August 20, 2007; 30(3): 282 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Huang and D. J. Tindall Dynamic FoxO transcription factors J. Cell Sci., August 1, 2007; 120(15): 2479 - 2487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Doucet, A. P. Russell, B. Leger, R. Debigare, D. R. Joanisse, M.-A. Caron, P. LeBlanc, and F. Maltais Muscle Atrophy and Hypertrophy Signaling in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 261 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Southgate, B. Neill, O. Prelovsek, A. El-Osta, Y. Kamei, S. Miura, O. Ezaki, T. J. McLoughlin, W. Zhang, T. G. Unterman, et al. FOXO1 Regulates the Expression of 4E-BP1 and Inhibits mTOR Signaling in Mammalian Skeletal Muscle J. Biol. Chem., July 20, 2007; 282(29): 21176 - 21186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Li, R. E. Waters, S. I. Redfern, M. Zhang, L. Mao, B. H. Annex, and Z. Yan Oxidative Phenotype Protects Myofibers from Pathological Insults Induced by Chronic Heart Failure in Mice Am. J. Pathol., February 1, 2007; 170(2): 599 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Al-Regaiey, M. M. Masternak, M. S. Bonkowski, J. A. Panici, J. J. Kopchick, and A. Bartke Effects of Caloric Restriction and Growth Hormone Resistance on Insulin-Related Intermediates in the Skeletal Muscle J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2007; 62(1): 18 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Sacheck, J.-P. K. Hyatt, A. Raffaello, R. T. Jagoe, R. R. Roy, V. R. Edgerton, S. H. Lecker, and A. L. Goldberg Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases FASEB J, January 1, 2007; 21(1): 140 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. G. Ni, K. Berenji, N. Wang, M. Oh, N. Sachan, A. Dey, J. Cheng, G. Lu, D. J. Morris, D. H. Castrillon, et al. Foxo Transcription Factors Blunt Cardiac Hypertrophy by Inhibiting Calcineurin Signaling Circulation, September 12, 2006; 114(11): 1159 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. T. Samuel, C. S. Choi, T. G. Phillips, A. J. Romanelli, J. G. Geisler, S. Bhanot, R. McKay, B. Monia, J. R. Shutter, R. A. Lindberg, et al. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes, July 1, 2006; 55(7): 2042 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Reecy, D. M. Spurlock, and C. H. Stahl Gene expression profiling: Insights into skeletal muscle growth and development J Anim Sci, April 1, 2006; 84(13_suppl): E150 - E. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Noguchi, M. Fujita, K. Murayama, R. Kurokawa, and I. Nishino Gene expression analyses in X-linked myotubular myopathy Neurology, September 13, 2005; 65(5): 732 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Skurk, Y. Izumiya, H. Maatz, P. Razeghi, I. Shiojima, M. Sandri, K. Sato, L. Zeng, S. Schiekofer, D. Pimentel, et al. The FOXO3a Transcription Factor Regulates Cardiac Myocyte Size Downstream of AKT Signaling J. Biol. Chem., May 27, 2005; 280(21): 20814 - 20823. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
